SXTP Stock Forecast & Price Target

60 Degrees is a specialty pharmaceutical company with a focus on developing and commercializing new therapies for infectious diseases. The company's pipeline is strong with three promising products under development, including tafenoquine and botanical extracts. The company has recently announced collaborations to increase patient access and affordability for ARAKODA, which is expected to support future revenue growth. Although there are risks associated with regulatory approvals and dilution from capital raises, the company's high growth prospects and potential for partnerships and expansion into new indications make it an attractive investment opportunity with a 130% upside potential. However, further progress on these fronts is necessary to reach the price target.

60 Degrees is facing financial challenges with a cash burn of $7 million in FY2025 and a recent $2.5 million ATM raise. However, the company has multiple shots on goal with their differentiated, FDA-approved product tafenoquine and potential supplementary NDA submission in 2026, as well as the potential for business development opportunities with their infectious disease portfolio. Despite these positive aspects, the company's need for additional financing and limited cash runway remain a concern for our negative outlook.